1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,480 | 3,700 | 20:59 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | JUNSHI BIO (01877): (1) PROPOSED ADOPTION OF THE 2025 H SHARE OPTION INCENTIVE SCHEME; (2) PROPOSED GRANT OF H SHARE OPTIONS TO THE GRANTEES; (3) PROPOSED ... | 1 | HKEx | ||
| Di | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - JT118 RECEIVED THE NOTICE OF APPROVAL FOR CLINICAL TRIAL | 1 | HKEx | ||
| Di | JPMorgan stuft Shanghai Junshi Biosciences auf 'Underweight' herab | 1 | Investing.com Deutsch | ||
| Di | JPMorgan downgrades Shanghai Junshi Biosciences stock to Underweight | 1 | Investing.com | ||
| Fr | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE CONVENING OF THE 2025 INTERIM RESULTS ... | 3 | HKEx | ||
| 27.08. | Treos Bio Corp.: TREOS Bio Partners with Charité Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer | 207 | GlobeNewswire (Europe) | Bridge financing of $2.1 million supports initiation of pivotal Phase II study in 140 patients with microsatellite stable metastatic colorectal cancer, addressing 85% of CRC cases with limited treatment... ► Artikel lesen | |
| 27.08. | Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates | 358 | GlobeNewswire (Europe) | SHANGHAI, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 26.08. | JUNSHI BIO (01877): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025 | 1 | HKEx | ||
| SHANGHAI JUNSHI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 26.08. | JUNSHI BIO (01877): CHANGE IN REGISTERED CAPITAL, PROPOSED ABOLISHMENT OF THE BOARD OF SUPERVISORS, AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ... | 1 | HKEx | ||
| 26.08. | JUNSHI BIO (01877): TERMS OF REFERENCE OF THE COMPLIANCE COMMITTEE OF THE BOARD OF DIRECTORS | - | HKEx | ||
| 26.08. | JUNSHI BIO (01877): TERMS OF REFERENCE OF THE STRATEGIC COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 26.08. | JUNSHI BIO (01877): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | - | HKEx | ||
| 26.08. | JUNSHI BIO (01877): TERMS OF REFERENCE OF THE REMUNERATION AND APPRAISAL COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 26.08. | JUNSHI BIO (01877): TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS | - | HKEx | ||
| 26.08. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* SPECIAL REPORT ON THE DEPOSIT AND ACTUAL USE OF PROCEEDS ... | - | HKEx | ||
| 14.08. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE PLAN FOR THE REDUCTION IN THE SHAREHOLDING ... | 1 | HKEx | ||
| 14.08. | JUNSHI BIO (01877): DATE OF BOARD MEETING | - | HKEx | ||
| 08.08. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE SUPPLEMENTAL NEW DRUG APPLICATION FOR TORIPALIMAB AS THE FIRST-LINE TREATMENT OF HER2-EXPRESSING ... | - | HKEx | ||
| 08.08. | Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma | 423 | GlobeNewswire (Europe) | SHANGHAI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 20.06. | JUNSHI BIO (01877): POLL RESULTS OF THE 2024 ANNUAL GENERAL MEETING | - | HKEx |
1 2 3 4 Weiter >>
64 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,170 | -0,05 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten Staaten an | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Anleiheemission
QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 28,890 | +0,10 % | Jefferies raises Mineralys Therapeutics stock price target to $26 from $15 | ||
| BEAM THERAPEUTICS | 18,250 | +11,89 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| KALARIS THERAPEUTICS | 4,400 | +10,00 % | Kalaris Therapeutics, Inc.: Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates | Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 46,910 | -0,68 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| EVOTEC | 5,860 | +1,21 % | BioNTech Aktie: Kurssturz? - Circus, Commerzbank, Evotec, Puma und SFC Energy im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| IMMUNOVANT | 16,490 | +9,42 % | Immunovant reports promising remission data for Graves' disease therapy | ||
| BIONTECH | 85,75 | -0,87 % | Ryvu Therapeutics to Support Clinical Trials for BioNTech in Poland | ||
| ADMA BIOLOGICS | 16,960 | -1,40 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,585 | -1,61 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
| ARS PHARMACEUTICALS | 10,915 | -1,71 % | ARS Pharma drops 9% as Lupin files application for generic neffy | ||
| SUMMIT THERAPEUTICS | 23,400 | -1,85 % | Summit Therapeutics stock maintains Buy rating at H.C. Wainwright on ivonescimab progress | ||
| HARMONY BIOSCIENCES | 37,190 | +0,27 % | Harmony Biosciences Holdings, Inc.: Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress | Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30... ► Artikel lesen | |
| CG ONCOLOGY | 27,680 | +0,80 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
| VERA THERAPEUTICS | 22,720 | +0,49 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen |
Das Unternehmen SHANGHAI JUNSHI BIOSCIENCES CO LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,480 Euro und damit -4,92 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI JUNSHI BIOSCIENCES CO LTD finden Sie auf Wallstreet Online.